Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease

Medicina (Lithuania)

Volumn 48, Issue 6, 2012, Pages 292-298

  Balode, Liga ^a   Strazda, Gunta ^a   Jurka, Normunds ^a   Kopeika, Uldis ^a,b   Kislina, Agnese ^a   Bukovskis, Maris ^a   Beinare, Marina ^a   Gardjušina, Valentina ^a   Taivans, Immanuels ^a  

^a UNIVERSITY OF LATVIA   (Latvia)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Leukotriene B4; Lipoxin A4

Indexed keywords

LEUKOTRIENE B4; LIPOXIN; LIPOXIN A;

ARTICLE; CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOLOGY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; SPUTUM;

FEMALE; HUMANS; LEUKOTRIENE B4; LIPOXINS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 84866600542     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6:524-6.
2. Garcia-Aymerich J, Agusti A, Barbera JA, Belda J, Farrero E, Ferrer A, et al. Phenotypic heterogeneity of chronic obstructive pulmonary disease. Arch Bronconeumol 2009; 45(3): 133-42.
3. Singh S. Chronic obstructive pulmonary disease. Curr Anaest Crit Care 2003;14:74-80.
4. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 2003;112:819-27.
5. Simoni-Wastila L, Blanshette CM, Qian J, Yang HK, Zhao L, Zuckerman IH, et al. Burden of chronic obstructive pulmonary disease in medicare beneficiaries residing in longterm care facilities. Am J Geriatr Pharmacother 2009;7(5): 262-70.
6. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 2005;73: 163-77.
7. Ryan A, Godson C. Lipoxins: regulators of resolution. Curr Opin in Pharmacol 2010;10:166-72.
8. Widegren H, Andersson M, Borgeat P, Flamand L, Johnston S, Greiff L. LtB4 increases nasal neutrophil activity and conditions neutrophils to exert antiviral effects. Respir Med 2011;105(7):997-1006.
9. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 2005;174:589-94.
10. Kostikas K, Gaga M, Papatheodorou G, Karamanis T, Orphanidou D, Loukides S. Leukotiene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest 2005;127:1553-9.
11. McMahon B, Godson C. Lipoxins: endogenous regulators of inflammation. Am J Physiol Renal Physiol 2004;286: F189-201.
12. Karp CL, Flick LM, Yang R, Uddin J, Petasis NA. Cystic fibrosis and lipoxins. Prostaglandins Leukot Essent Fatty Acids 2005;73:263-70.
13. Haworth O, Levy BD. Endogenous lipid mediators in the resolution of airway inflammation. Eur Respir J 2007;30: 980-92.
14. Vachier I, Bonnans C, Chavis C, Farce M, Godard P, Bousquet J, et al. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005;115:55-60.
15. Corhay JL, Henket M, Nguyen D, Duysinx B, Sele J, Louis R. Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD. Chest 2009; 136:1047-54.
16. Ko FWS, Leung TF, Wong GWK, Ngai J, To KW, Ng S, et al. Measurement of tumour necrosis factor-alpha, leukotriene B4, and interleukin 8 in exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009; 4:79-86.
17. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
18. Pizzichini E, Pizzichiani MMM, Leigh R, Djukanovic R, Sterk PJ. Safety of sputum induction. Eur Respir J Suppl 2002;37:9s-18s.
19. Amer M, Elnasser TA, El Hagger S, Mostafa T, Abdel-Malak G, Zohdy W. May-Grunwald-Giemse stain for detection of spermatogenic cells in the ejaculate: a simple predictive parameter for successful testicular sperm retrieval. Hum Reprod 2001;16(7):1427-32.
20. Zar JH. Biostatistical analysis. In: Snavely SL, editor. 4th ed. New Jersey: Prentice-Hall, Inc. Simon & Schuster/AViacom Company; 1999. p. 275, 278, 353.
21. Bhavsar PK, Levy BD, Hew MJ, Pfeffer MA, Kazani S, Israel E, et al. Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma. Respir Res 2010;11:71-9.
22. Chiang N, Schwab JM, Fredman G, Kasuga K, Gelman S, Serhan CN. Anesthetics impact the resolution of inflammation. PLoS One 2008;3(4):e1879.
23. D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, et al. CD4+CD25+Foxp3+Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest 2009;119(10):2898 913.
24. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbation of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000;15:274-280
25. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LAJ, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007;21(2):325-32.
26. Pettipher ER, Salter ED, Breslow R, Raycroft L, Showell HJ. Specific inhibition of leukotriene B4 (LtB4)-induced neutrophil emigration by 20-hydroxy LtB4: implications for the regulation of inflammatory responses. Br J Pharmacol 1993;110(1):423-7.
27. Hankin JA, Murphy RC. The metabolism of leukotriene B4 in Lewis lung carcinoma porcine kidney cells. Am J Respir Crit Care Med 2000;161:S81-7.
28. Brom J, Schönfeld W, König W. Metabolism of leukotriene B4 by activated human polymorphonuclear granulocytes. Immunology 1988;64(3):509-18.
29. Kelly MM, Wightman PD, Berlyne GS, Leigh R, Morris MM, Hargreave FE. Repeability of leukotriene measurements in induced sputum. Eur Respir J 2000;16:220S.
30. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 2009;71:451-64.
31. Isajevs S, Taivans I, Kopeika U, Strazda G. Inflammatory cells and HDAC2 expression in peripheral airways of COPD patients. Mod Pathol 2006;19(Suppl 3):167-8.
32. Malhotra D, Thimmulappa RK, Mercado N, Ito K, Kombairaju P, Kumar S, et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J Clin Invest 2011;121(11):4289-302.
33. Morales SA, Dreyse DJ, Díaz PO, Saldías PF, Carrasco M, Lisboa BC. Systemic inflammation among stable ex smokers with chronic obstructive pulmonary disease. Rev Med Chil 2010;138(8):957-64.
34. Papaioannou AI, Loukides S, Minas M, Kontogianni K, Bakakos P, Gourgoulianis KI, et al. Exhaled breath condensate pH as a biomarker of COPD severity in ex-smokers. Respir Res 2011;12:67-73.
35. Miller M, Cho JY, Pham A, Friedman PJ, Ramsdell J, Broide DH. Persistent airway inflammation and emphysema progression on CT scan in ex-smokers observed for 4 years. Chest 2011;139(6):1380-7.
36. Shields AM, Panayi GS, Corrigall VM. Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis? Clin Exp Immunol 2011;165(3): 292-300.
37. Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford WJ, Serhan CN, et al. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J 2007;21:3877-84.
38. Petasis NA, Keledjian R, Sun YP, Nagulapalli KC, Tjonahen E, Yang R, et al. Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorg Med Chem Lett 2008;18(4):1382-7.